Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
214 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diabetic Nephropathy - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Pipeline Review, H2 2017, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape. Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 14, 10, 1, 32, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively. Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Diabetic Nephropathy - Overview 8 Diabetic Nephropathy - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 14 Products under Development by Companies 15 Products under Development by Universities/Institutes 19 Diabetic Nephropathy - Therapeutics Assessment 20 Assessment by Target 20 Assessment by Mechanism of Action 23 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Diabetic Nephropathy - Companies Involved in Therapeutics Development 30 AbbVie Inc 30 Allergan Plc 30 Antisense Therapeutics Ltd 31 Aptevo Therapeutics Inc 31 Araim Pharmaceuticals Inc 32 Arena Pharmaceuticals Inc 32 Astellas Pharma Inc 33 AstraZeneca Plc 33 Bayer AG 34 BLR Bio LLC 34 Boehringer Ingelheim GmbH 35 Cellmid Ltd 35 ChemoCentryx Inc 36 CSL Ltd 36 Daiichi Sankyo Company Ltd 37 DiaMedica Therapeutics Inc 37 Dynamis Therapeutics Inc 38 Galectin Therapeutics Inc 38 GenKyoTex SA 39 Gilead Sciences Inc 39 GNI Group Ltd 40 Islet Sciences Inc 40 Johnson & Johnson 41 MediPost Co Ltd 41 Mesoblast Ltd 42 Mitsubishi Tanabe Pharma Corp 42 MorphoSys AG 43 Noxxon Pharma AG 43 Omeros Corp 44 Paranta Biosciences Ltd 44 PhiloGene Inc 45 PhytoHealth Corp 45 ProMetic Life Sciences Inc 46 Redx Pharma Plc 46 Sarfez Pharmaceuticals Inc 47 Serodus ASA 47 Teijin Pharma Ltd 48 Theravance Biopharma Inc 48 Twoxar Inc 49 Vascular Pharmaceuticals Inc 49 Vicore Pharma AB 49 XORTX Pharma Corp 50 Diabetic Nephropathy - Drug Profiles 51 11-RVIVIT - Drug Profile 51 A-717 - Drug Profile 52 Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile 53 apararenone - Drug Profile 54 APD-371 - Drug Profile 55 APX-115 - Drug Profile 57 ASP-8232 - Drug Profile 58 atesidorsen sodium - Drug Profile 59 atrasentan hydrochloride - Drug Profile 66 BI-685509 - Drug Profile 68 BI-690517 - Drug Profile 69 BI-703704 - Drug Profile 70 BLR-200 - Drug Profile 71 C-21 - Drug Profile 72 canagliflozin - Drug Profile 75 CCX-140 - Drug Profile 82 Cell Therapy for Chronic Kidney Disease and Metabolic Disorders - Drug Profile 86 cenicriviroc mesylate - Drug Profile 87 cibinetide - Drug Profile 95 CSL-346 - Drug Profile 98 Cyndacel-M - Drug Profile 99 DM-199 - Drug Profile 101 DM-399 - Drug Profile 106 Drugs for Diabetic Nephropathy - Drug Profile 107 DT-23552 - Drug Profile 108 DYN-12 - Drug Profile 109 emapticap pegol - Drug Profile 111 esaxerenone - Drug Profile 113 finerenone - Drug Profile 116 FM-1302 - Drug Profile 118 GKT-136901 - Drug Profile 119 GKT-831 - Drug Profile 121 GLY-230 - Drug Profile 125 GRMD-02 - Drug Profile 126 GS-444217 - Drug Profile 140 IL-233 - Drug Profile 141 IP-9 - Drug Profile 142 JD-5037 - Drug Profile 143 JNJ-39933673 - Drug Profile 144 MG-132 - Drug Profile 145 Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile 146 MOR-107 - Drug Profile 148 MPC-300IV - Drug Profile 149 Orbcel-M - Drug Profile 155 PBI-4050 - Drug Profile 156 PBI-4425 - Drug Profile 164 PBI-4547 - Drug Profile 165 PHN-033 - Drug Profile 166 pirfenidone - Drug Profile 167 Recombinant Protein for Diabetic Nephropathy - Drug Profile 169 Recombinant Protein to Antagonize VEGFR-2 for Diabetic Nephropathy and Oncology - Drug Profile 170 REDX-06109 - Drug Profile 171 SCO-272 - Drug Profile 172 SER-150 - Drug Profile 173 Small Molecules for Diabetic Nephropathy - Drug Profile 176 Small Molecules to Inhibit AOC3 for Diabetic Nephropathy - Drug Profile 177 Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy - Drug Profile 178 Small Molecules to Inhibit Rho Kinase for Hypertension and Diabetic Nephropathy - Drug Profile 179 SP-20202 - Drug Profile 180 Stem Cell Therapy for Diabetic Nephropathy and Autoimmune Disorders - Drug Profile 181 TBE-31 - Drug Profile 182 TD-0714 - Drug Profile 183 TD-1439 - Drug Profile 185 TMX-049 - Drug Profile 186 TNFR x TWEAKR - Drug Profile 187 VAR-400 - Drug Profile 188 VPI-2690B - Drug Profile 189 VS-105 - Drug Profile 190 Wnt-001 - Drug Profile 191 XRX-108 - Drug Profile 192 XRX-221 - Drug Profile 193 Diabetic Nephropathy - Dormant Projects 194 Diabetic Nephropathy - Discontinued Products 197 Diabetic Nephropathy - Product Development Milestones 198 Featured News & Press Releases 198 Appendix 208 Methodology 208 Coverage 208 Secondary Research 208 Primary Research 208 Expert Panel Validation 208 Contact Us 208 Disclaimer 209
List of Tables
Number of Products under Development for Diabetic Nephropathy, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Diabetic Nephropathy - Pipeline by AbbVie Inc, H2 2017 Diabetic Nephropathy - Pipeline by Allergan Plc, H2 2017 Diabetic Nephropathy - Pipeline by Antisense Therapeutics Ltd, H2 2017 Diabetic Nephropathy - Pipeline by Aptevo Therapeutics Inc, H2 2017 Diabetic Nephropathy - Pipeline by Araim Pharmaceuticals Inc, H2 2017 Diabetic Nephropathy - Pipeline by Arena Pharmaceuticals Inc, H2 2017 Diabetic Nephropathy - Pipeline by Astellas Pharma Inc, H2 2017 Diabetic Nephropathy - Pipeline by AstraZeneca Plc, H2 2017 Diabetic Nephropathy - Pipeline by Bayer AG, H2 2017 Diabetic Nephropathy - Pipeline by BLR Bio LLC, H2 2017 Diabetic Nephropathy - Pipeline by Boehringer Ingelheim GmbH, H2 2017 Diabetic Nephropathy - Pipeline by Cellmid Ltd, H2 2017 Diabetic Nephropathy - Pipeline by ChemoCentryx Inc, H2 2017 Diabetic Nephropathy - Pipeline by CSL Ltd, H2 2017 Diabetic Nephropathy - Pipeline by Daiichi Sankyo Company Ltd, H2 2017 Diabetic Nephropathy - Pipeline by DiaMedica Therapeutics Inc, H2 2017 Diabetic Nephropathy - Pipeline by Dynamis Therapeutics Inc, H2 2017 Diabetic Nephropathy - Pipeline by Galectin Therapeutics Inc, H2 2017 Diabetic Nephropathy - Pipeline by GenKyoTex SA, H2 2017 Diabetic Nephropathy - Pipeline by Gilead Sciences Inc, H2 2017 Diabetic Nephropathy - Pipeline by GNI Group Ltd, H2 2017 Diabetic Nephropathy - Pipeline by Islet Sciences Inc, H2 2017 Diabetic Nephropathy - Pipeline by Johnson & Johnson, H2 2017 Diabetic Nephropathy - Pipeline by MediPost Co Ltd, H2 2017 Diabetic Nephropathy - Pipeline by Mesoblast Ltd, H2 2017 Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017 Diabetic Nephropathy - Pipeline by MorphoSys AG, H2 2017 Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H2 2017 Diabetic Nephropathy - Pipeline by Omeros Corp, H2 2017 Diabetic Nephropathy - Pipeline by Paranta Biosciences Ltd, H2 2017 Diabetic Nephropathy - Pipeline by PhiloGene Inc, H2 2017 Diabetic Nephropathy - Pipeline by PhytoHealth Corp, H2 2017 Diabetic Nephropathy - Pipeline by ProMetic Life Sciences Inc, H2 2017 Diabetic Nephropathy - Pipeline by Redx Pharma Plc, H2 2017 Diabetic Nephropathy - Pipeline by Sarfez Pharmaceuticals Inc, H2 2017 Diabetic Nephropathy - Pipeline by Serodus ASA, H2 2017 Diabetic Nephropathy - Pipeline by Teijin Pharma Ltd, H2 2017 Diabetic Nephropathy - Pipeline by Theravance Biopharma Inc, H2 2017 Diabetic Nephropathy - Pipeline by Twoxar Inc, H2 2017 Diabetic Nephropathy - Pipeline by Vascular Pharmaceuticals Inc, H2 2017 Diabetic Nephropathy - Pipeline by Vicore Pharma AB, H2 2017 Diabetic Nephropathy - Pipeline by XORTX Pharma Corp, H2 2017 Diabetic Nephropathy - Dormant Projects, H2 2017 Diabetic Nephropathy - Dormant Projects, H2 2017 (Contd..1), H2 2017 Diabetic Nephropathy - Dormant Projects, H2 2017 (Contd..2), H2 2017 Diabetic Nephropathy - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
